Start Time: 08:30 January 1, 0000 9:06 AM ET

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)
Q1 2024 Earnings Conference Call
May 02, 2024, 08:30 AM ET

Company Participants

Saqib Islam - CEO
Francis Perier - CFO
Bhavesh Ashar - Chief Commercial Officer
Jim Cassidy - CMO
Samantha Sandler - Senior Director of IR

Conference Call Participants

Anupam Rama - JPMorgan
Yaron Werber - TD Cowen
Corinne Johnson - Goldman Sachs
Peter Lawson - Barclays
Alec Stranahan - Bank of America
Michael Schmidt - Guggenheim

Operator

Good morning. My name is Tawanda, and I will be your conference operator today. At this time, I would like to welcome everyone to the SpringWorks Therapeutics First Quarter 2024 Earnings Conference Call. [Operator Instructions]. Thank you.

I would now like to hand the conference over to Samantha Sandler, Senior Director of Investor Relations at SpringWorks Therapeutics. Samantha, you may now begin the conference.

Samantha Sandler

Thank you, and good morning, everyone. Welcome to SpringWorks Therapeutics First Quarter 2024 Earnings Conference Call. This morning, we issued a press release, which outlines the topics we plan to discuss today. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors & Media section of our website at www.springworkstx.com.

Joining me today are Saqib Islam, Chief Executive Officer; Bhavesh Ashar, Chief Commercial Officer; Dr. Jim Cassidy, Chief Medical Officer; and Frank Perier, Chief Financial Officer. Dr. Badreddin Edris, Chief Operating Officer, is also on the line and available during Q&A.

Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements that are subject to a number of risks and uncertainties. These may cause our actual results to differ materially including those described in our reports filed with the SEC. You are cautioned not to place any undue reliance on these forward-looking statements, and SpringWorks disclaims any obligation to update such statements.

I will now turn the call over to Saqib.

Saqib Islam

Thank you, Sam, and thank you all for joining this morning. Today, I'm pleased to share our first quarter performance as well as our progress towards accomplishing our key objectives for 2024 and beyond. A top priority for SpringWorks is to continue to execute on our successful U.S. launch of OGSIVEO for desmoid tumors, and we are very pleased with our strong start. In the first quarter of 2024, our first full quarter on the market, we reported $21 million in net product revenue. This performance underscores the high unmet need for patients with desmoid tumors, the transformative benefits of OGSIVEO to these patients and strong execution across our commercial efforts.